PLA2-R positive primary membranous nephropathy: a case report
DOI:
https://doi.org/10.18203/2320-6012.ijrms20250267Keywords:
Membranous nephropathy, PLA2-R receptor, Nephrotic syndrome, Modified ponticelli, RituximabAbstract
Membranous nephropathy (MN) is a significant cause of nephrotic syndrome in adults, often linked to the presence of circulating antibodies against phospholipase A2 receptor (PLA2R). This case report details the clinical presentation, diagnostic process, treatment, and outcomes of a patient diagnosed with PLA2R-positive membranous nephropathy. The report highlights the importance of early diagnosis and personalized treatment strategies, demonstrating the evolving landscape of MN management. A brief review of the literature related to the topic is also presented. For this purpose, a search was made in freely accessible sources, selecting those with the most relevant and up-to-date information.
Metrics
References
Wang M, Yang J, Fang X, Lin W, Yang Y. Membranous nephropathy: pathogenesis and treatments. Med Comm. 2024;5(7):614. DOI: https://doi.org/10.1002/mco2.614
Efe O, So PN, Anandh U, Lerma EV, Wiegley N. An Updated Review of Membranous Nephropathy. Indian journal of nephrology. 2024;34(2):105. DOI: https://doi.org/10.25259/ijn_317_23
Bharati J, Waguespack DR, Beck LH. Membranous Nephropathy: Updates on Management. Advances in Kidney Disease and Health. 2024;31(4):299–308. DOI: https://doi.org/10.1053/j.akdh.2024.04.004
Hemanth Kumar MK, Sandhu J, Sandhu JS. Profile and primary treatment outcomes in membranous nephropathy. Saudi Med J. 2022;43:1051–6. DOI: https://doi.org/10.15537/smj.2022.43.9.20220459
Trinh K, Bose B. Membranous Nephropathy. In: Evidence-Based Nephrology, Second Ed. wiley; 2022;2:235–53. DOI: https://doi.org/10.1002/9781119105954.ch16
Ronco P, Beck L, Debiec H, Fervenza FC, Hou FF, Jha V, et al. Membranous nephropathy. Nature Reviews Disease Primers. 2021;7(1):1–23. DOI: https://doi.org/10.1038/s41572-021-00303-z
Sethi S, Beck LH, Glassock RJ, Haas M, De Vriese AS, Caza TN, et al. Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification. Kidney Int. 2023;104(6):1092–102. DOI: https://doi.org/10.1016/j.kint.2023.06.032
Van de Logt AE, Fresquet M, Wetzels JF, Brenchley P. The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery. Kidney Int. 2019;96(6):1292–302. DOI: https://doi.org/10.1016/j.kint.2019.07.014
Zhang J, Fan Z, Wang P, Zhang AH. Phospholipase A2 Receptor Antibodies and Clinical Prognosis in Patients with Idiopathic Membranous Nephropathy: An Updated Systematic Review and Meta-Analysis. Kidney Blood Press Res. 2023;48(1):102–13. DOI: https://doi.org/10.1159/000529415
Dantas M, Silva LBB, Pontes BTM, Dos Reis MA, De Lima PSN, Neto MM. Membranous nephropathy. Brazilian Journal of Nephrology. Sociedade Brasileira de Nefrologia; 2023;45:229–43. DOI: https://doi.org/10.1590/2175-8239-jbn-2023-0046en
Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Mao Chan T, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases kidney international. Kidney Int. 2021;100:1–276. DOI: https://doi.org/10.1016/j.kint.2021.05.021
Mathew GG, Sundaramurthy S, Muthuperumal P, Jayaprakash V. Low-dose Rituximab in the Treatment of Primary Membranous Nephropathy - A Systematic Review and Meta-Analysis. G Ital Nefrol. 2024;41(5):56.
Yu Y, Xu R, Li Z, Wan Q. Different Dosage Regimens of Rituximab in Primary Membranous Nephropathy Treatment: A Systematic Review. Int J Nephrol Renovasc Dis. 2024;17:265–73. DOI: https://doi.org/10.2147/IJNRD.S489455
McDonnell T, Wu HHL, Sinha S, Chinnadurai R. The Role of PLA2R in Primary Membranous Nephropathy: Do We Still Need a Kidney Biopsy. Genes. 2023;14(7):1343. DOI: https://doi.org/10.3390/genes14071343
Ronco P, Plaisier E, Debiec H. Advances in membranous nephropathy. J Clin Med. 2021;10(4):607. DOI: https://doi.org/10.3390/jcm10040607
Downloads
Published
How to Cite
Issue
Section
